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Abstract: The tumor microenvironment is a key factor in disease progression, local resistance,
immune-escaping, and metastasis. The rapid proliferation of tumor cells and the aberrant structure of
the blood vessels within tumors result in a marked heterogeneity in the perfusion of the tumor tissue
with regions of hypoxia. Although most of the tumor cells die in these hypoxic conditions, a part of
them can adapt and survive for many days or months in a dormant state. Dormant tumor cells are
characterized by cell cycle arrest in G0/G1 phase as well as a low metabolism, and are refractive to
common chemotherapy, giving rise to metastasis. Despite these features, the cells retain their ability
to proliferate when conditions improve. An understanding of the regulatory machinery of tumor
dormancy is essential for identifying early cancer biomarkers and could provide a rationale for the
development of novel agents to target dormant tumor cell populations. In this review, we examine
the current knowledge of the mechanisms allowing tumor dormancy and discuss the crucial role of
the hypoxic microenvironment in this process.
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1. Introduction
The tumor mass is composed not only by cancer cells but also by a variety of resident and
infiltrating host cells, secreted factors and extracellular matrix components, known as the tumor
microenvironment (TME). Tumor progression is influenced by interactions of cancer cells with their
environment that determine if the primary tumor is eradicated, metastasizes, or establishes dormant
micro-metastases. The TME can also influence therapeutic responses, justifying the recent research
studies on new therapeutic approaches that target components of the TME.
2. Tumor Microenvironment
TME consists of a complex network of components that regulates tumor initiation, malignant
progression and metastasis and has profound effects on therapeutic efficacy [1]. These elements can be
widely classified into three main groups: (i) cells of hematopoietic origin, (ii) cells of mesenchymal
origin, and (iii) non-cellular components (Figure 1) [2]. First, cells of hematopoietic origin arise in the
bone marrow and can be subdivided into cells of lymphoid lineage, consisting of T cells, B cells, natural
killer cells, and those of myeloid lineage, which include macrophages, neutrophils and myeloid-derived
suppressor cells. The different subsets of cells have either positive or negative effects on the outcome
of the tumor [3].
Then, cells of mesenchymal origin derive from the mesenchyme and include fibroblasts,
myofibroblasts, mesenchymal stem cells, adipocytes and endothelial cells. Fibroblast, myofibroblast,
and mesenchymal stem cells directly support cancer stem cells (CSCs) by creating a favourable niche
and facilitating tumor progression, while endothelial cells constitute the walls of blood vessels and
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have a major role in vascular function and angiogenesis. So far, adipocytes were thought only as energy
storage houses while recent studies have revealed the importance of factors secreted by adipocytes in
tumor progression [1].
Finally, the extracellular matrix, the major non-cellular component of the TME, is involved in the
formation of a stem cell niche. Although it acts to maintain tissue architecture and prevent cancer
cells formation, an abnormal extracellular matrix has been shown to promote tumor growth and
angiogenesis [4].
Many hallmarks of cancer are related to TME, including the ability to induce proliferation and
inhibit apoptosis, to reprogram metabolism, to increase factors that support cancer invasion and
metastasis, and to promote angiogenesis. Because the rapid proliferation of the cells requires an
accelerated production of basic cellular building blocks, differences in cellular metabolic programs
occur within the cells of TME and some proteins, such as HIF-1α, PI3K, AKT, p53, PTEN, known
as crucial components in the metabolic pathways, can be differently regulated in cancer cells [5].
Although recent studies have revealed the importance of fatty acids and proteins as fuel sources for
cancer cells, aerobic glycolysis remains the major fuel source for tumor cells [6]. It is well described
that cancer cells can metabolize 10-fold more glucose than normal tissues to produce lactate. Despite
enhanced glycolysis, most cancer cells also maintain mitochondrial respiration to produce a significant
amount of ATP. The metabolic switch of cancer cells toward a more glycolytic phenotype increases the
concentration of protons [H+], causing the acidification of cytoplasm. To overcome low intracellular
pH (pHi), cancer cells employ a large redundancy of mechanisms, such as the activation of plasma
membrane proton pump ATPase (V-ATPase), carbonic anhydrases (CAIXs) and Na+/H+ exchangers or
anion exchangers that determine a slow increase of pHi. In response to H+ eﬄux, the pH of tumor
extracellular space (pHe) becomes acidic, forming a reversed pH gradient. The acidosis of TME
promotes cancer progression and induces migration and invasion [7].Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 3 of 21 
 
 
Figure 1. Components of tumor microenvironment. Tumor microenvironment (TME) is a complex 
network composed of extracellular matrix, cells of hematopoietic origin (immune and inflammatory 
cells) and cells of mesenchymal origin (fibroblasts, endothelial cells, adipocytes). The interaction 
between tumor and its microenvironment is crucial for cancer development. Tumor cells promote 
angiogenesis, induce inflammatory response, stimulate transformation of normal fibroblasts (NF) and 
mesenchymal stem cells towards cancer-associated fibroblasts (CAF). On the other hand, mesenchymal 
stem cells as well as immune cells promote and regulate tumor metastasis or dormancy, endothelial cells 
induce tumor cell proliferation and adipocytes play a crucial role in tumor cell invasion. 
2.1. Hypoxia in Tumor Microenvironment 
Due to rapid cell growth and abnormalities of the vasculature network, most solid tumors 
present disrupted O2 homeostasis that results in regions of hypoxia exhibiting oxygenation levels 
even lower than their tissue of origin [10]. In this microenvironment cells undergo genetic and 
adaptive changes that allow them to survive and even proliferate. 
Based on pathogenesis and time frames three subtypes of tumor hypoxia have been described 
[11]. Acute hypoxia or ‘perfusion-limited’ hypoxia mainly results from transient perturbation in 
perfusion (e.g., vascular occlusion by cell aggregates), fluctuating red blood cell fluxes or short-term 
contractions of the interstitial matrix. The time frame of acute hypoxia is variable in tumors, and it 
can last from several minutes up to a few days. Acute hypoxia allows cells to survive by activating 
different mechanisms such as autophagy that is achieved by decreasing oxidative metabolism. 
Chronic hypoxia or “diffusion-related” hypoxia is mainly a consequence of a limited diffusion 
of oxygen with tumor mass expansion. Longer exposure to hypoxia determines long-term cellular 
changes. Since chronic hypoxia hampers DNA repair systems leading to genetic instability and 
mutagenesis, it is associated with a high frequency of DNA breaks and the accumulation of DNA 
replication errors. Moreover, chronic hypoxia induces metabolic switch from oxidative 
phosphorylation to anaerobic glycolysis that leads to continuous lactate production from pyruvate 
resulting in acidosis [12]. Although both acute and chronic hypoxia increase resistance to therapy, 
the latter is associated with a more aggressive tumor phenotype through the development of micro-
niches of quiescent cells and induction of spontaneous metastasis [13–15]. 
A third type of hypoxia, called cycling hypoxia, is characterized by oxygen fluctuations with 
periods of deep hypoxia and moderate hypoxia, and is more commonly associated to hypoxia-
reoxygenation profile [16,17]. Cycling hypoxia probably represents the oxygenation state that better 
reflects in vivo situation. The biological responses activated by reoxygenation can instigate 
continuous adaptive mechanisms that contribute to increase the aggressiveness of the cancer cells. 
Some authors report that high level of reactive oxygen species (ROS) induced by cycling hypoxia may 
Figure 1. Components of tumor microenvironment. Tumor microenvironment (TME) is a complex
network composed of extracellular matrix, cells of hematopoietic origin (immune and inflammatory
cells) and cells of mesenchymal origin (fibroblasts, endothelial cells, adipocytes). The interaction
between tumor and its microenvironment is crucial for cancer development. Tumor cells promote
angiogenesis, induce inflammatory response, stimulate transformation of normal fibroblasts (NF) and
mesenchymal stem cells towards cancer-associated fibroblasts (CAF). On the other hand, mesenchymal
stem cells as well as immune cells promote and regulate tumor metastasis or dormancy, endothelial
cells induce tumor cell proliferation and adipocytes play a crucial role in tumor cell invasion.
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Moreover, TME is characterized by disorganized blood vessels that are immature, tortuous
and hyperpermeable. The tumor vasculature is typically a complex labyrinth of vessels in which
arterioles, capillaries and venules are not clearly identifiable. Furthermore, tumor vessels are more
permeable than normal ones because they are poorly invested with smooth muscle cells and have
a discontinuous endothelial cell lining with an abnormal basement membrane. Increased vessel
permeability results in aberrant osmotic forces, leading to the accumulation of vascular contents and
elevated interstitial fluid pressure. As result, the irregular vasculature leads to impaired tumoral
blood flow that cannot supply nutrient to cells and remove waste products. In addition, the aberrant
geometry of vessels causes an inadequate oxygen supply to tumor cells with hypoxia micro-regional.
These particular characteristics of tumor vasculature lead to adverse micro-environmental conditions
that obstruct traditional therapeutic anti-cancer strategies [8,9]. Overall, the identification of the most
important molecular players in TME represents the first step toward the formulation of new therapeutic
cancer treatment.
2.1. Hypoxia in Tumor Microenvironment
Due to rapid cell growth and abnormalities of the vasculature network, most solid tumors present
disrupted O2 homeostasis that results in regions of hypoxia exhibiting oxygenation levels even lower
than their tissue of origin [10]. In this microenvironment cells undergo genetic and adaptive changes
that allow them to survive and even proliferate.
Based on pathogenesis and time frames three subtypes of tumor hypoxia have been described [11].
Acute hypoxia or ‘perfusion-limited’ hypoxia mainly results from transient perturbation in perfusion
(e.g., vascular occlusion by cell aggregates), fluctuating red blood cell fluxes or short-term contractions
of the interstitial matrix. The time frame of acute hypoxia is variable in tumors, and it can last from
several minutes up to a few days. Acute hypoxia allows cells to survive by activating different
mechanisms such as autophagy that is achieved by decreasing oxidative metabolism.
Chronic hypoxia or “diffusion-related” hypoxia is mainly a consequence of a limited diffusion of
oxygen with tumor mass expansion. Longer exposure to hypoxia determines long-term cellular changes.
Since chronic hypoxia hampers DNA repair systems leading to genetic instability and mutagenesis,
it is associated with a high frequency of DNA breaks and the accumulation of DNA replication errors.
Moreover, chronic hypoxia induces metabolic switch from oxidative phosphorylation to anaerobic
glycolysis that leads to continuous lactate production from pyruvate resulting in acidosis [12]. Although
both acute and chronic hypoxia increase resistance to therapy, the latter is associated with a more
aggressive tumor phenotype through the development of micro-niches of quiescent cells and induction
of spontaneous metastasis [13–15].
A third type of hypoxia, called cycling hypoxia, is characterized by oxygen fluctuations with periods
of deep hypoxia and moderate hypoxia, and is more commonly associated to hypoxia-reoxygenation
profile [16,17]. Cycling hypoxia probably represents the oxygenation state that better reflects in vivo
situation. The biological responses activated by reoxygenation can instigate continuous adaptive
mechanisms that contribute to increase the aggressiveness of the cancer cells. Some authors report that
high level of reactive oxygen species (ROS) induced by cycling hypoxia may contribute to tumor cells
survival and progression [16,18]. Thus, the chemoresistance, the radio-resistance and the ability to
proliferate or metastasize are extensively enhanced during hypoxia/reoxygenation cycles.
2.2. Hypoxia Inducible Factors in Tumor Microenvironment
Hypoxic signaling is mainly mediated via the hypoxia-inducible transcription factors (HIFs),
that induce genes involved in angiogenesis, growth and cell survival, energy metabolism, invasion
and metastasis.
HIFs are heterodimeric transcription factors consisting in a stable and constitutively expressed
β-subunit (HIF-β) and an oxygen sensitive α-subunit (HIF-α), that under normoxia is targeted
to proteasomal degradation. Both subunits contain basic helix-loop-helix and PER-ARNT-SIM
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(PAS) domains that are important for DNA binding and dimerization. The HIF-α subunit also
contains an oxygen-dependent degradation domain (ODD) that regulates the oxygen-dependent
degradation [19–21]. To date, three isoforms of HIF-α subunit (HIF-1α, HIF-2α and HIF-3α) have been
described, among which HIF-1α and HIF-2α are the best characterized. While HIF-1α is expressed
ubiquitously, HIF-2α is expressed in a more restricted number of cell types such as hepatocytes and
endothelial cells. HIF-1α and HIF-2α have a similar C-terminal transactivation domain (C-TAD),
which contributes to the transcription of their shared targets. The differences in their N-terminal
transactivation domain (N-TAD) confer the different binding capabilities and specificity among their
targets [22]. HIF-3α is the most different from the three isoforms and lacks the C-TAD [23].
In the presence of oxygen, conserved proline residues on the α-subunit are hydroxylated
promoting its degradation. This hydroxylation is mediated by prolyl-4-hydroxylases (PHDs), oxygen,
iron, and ascorbate dependent enzymes belonging to the 2-oxoglutarate-dependent oxygenase
superfamily [24]. The hydroxylation of HIF-α allows the rapid interaction with the von Hippel-Lindau
tumor-suppression protein (VHL), a component of E3 ubiquitin ligase complex which tags HIF-α for
proteasomal degradation.
HIF transcriptional activity is also regulated by a second oxygen-sensitive hydroxylation event
mediated by factor inhibiting HIF-1 (FIH-1) [25,26]. FIH-1 is a 2-oxoglutarate-dependent oxygenase
that hydroxylate an asparagine residue in the C-TAD of HIF-α, thereby impairing interaction with the
p300/CBP co-activator [27].
Thus, controlling both the degradation and inactivation of HIF-1α subunit, PHDs and FIHs ensure
full repression of the HIF pathway under normoxia. On the other hand, when the oxygen level drops,
the hydroxylases lose their activity and HIF-1α is stabilized and translocates into the nucleus where it
dimerizes with HIF-1β subunit. HIF complex binds to DNA in the hypoxia-response elements (HRE)
region and promotes genes transcription (Figure 2) [28].Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 5 of 21 
 
 
Figure 2. Canonical regulation of HIF-1α stability. In oxygenated conditions, HIF-1α is hydroxylated 
on proline residues by prolyl-4-hydroxylases (PHDs) and polyubiquitinated by the von Hippel–
Lindau protein (pVHL). This leads to degradation of HIF-1α by the 26S proteasome system. The 
oxygen-dependent hydroxylation of asparagine residue by the enzyme FIH-1 impairs p300 and CBP 
binding and inhibits HIF-1 mediated gene transcription. In hypoxic conditions, HIF-1α is stabilized 
and translocated into the nucleus, where it binds to its dimerization partner HIF-1and enhances the 
transcription of HIF target genes. 
In most in vitro chronic hypoxia studies, HIF-1α subunit levels are increased and stabilized 
within few hours, but after few days decrease to lower expression levels. This is likely due to the HIF-
1-mediated up-regulation of PHD2, which retains enough activity to hydroxylate HIF-1α, resulting 
in its renewed degradation [29]. Cycling hypoxia results in an enhanced activity and stabilization of 
HIF-1α, which is at a much greater level than that in chronic hypoxia [30]. This damaging phenotype, 
where HIF-1α is accumulated, is also associated with an increased resistance to radiotherapy and 
chemotherapy as well as increased metastatic potential [12]. 
During hypoxia, HIFs support and even enhance the metabolic reprogramming of glycolysis 
through the up-regulation of almost all glycolytic genes, like hexokinase 1 and 3, aldolase A and C and 
glyceraldehyde 3-phosphate dehydrogenase-6, and the monocarboxylate transporters that export lactate. 
HIFs also regulate a set of genes involved in extracellular matrix remodeling, migration and 
digestion of the basement membrane. This group includes vimentine, fibronectine, keratins, matrix 
metalloproteinase 2, and cathepsin D that is associated with a concomitant loss of E-cadherin, a 
crucial feature of epithelium-mesenchyme transition [31]. The principal HIF-1α regulated genes are 
reported in Figure 3. 
Figure 2. Canonical regulation of HIF-1α stability. In oxygenated conditions, HIF-1α is hydroxylated
on proline residues by prolyl-4-hydroxylases (PHDs) and polyubiquitinated by the von Hippel–Lindau
protein (pVHL). This leads to degradation of HIF-1α by the 26S proteasome system. The oxygen-
dependent hydroxylation of asparagine residue by the enzyme FIH-1 impairs p300 and CBP binding
and inhibits HIF-1 mediated gene transcription. In hypoxic conditions, HIF-1α is stabilized and
translocated into the nucleus, where it binds to its dimerization partner HIF-1β and enhances the
transcription of HIF target genes.
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In most in vitro chronic hypoxia studies, HIF-1α subunit levels are increased and stabilized
within few hours, but after few days decrease to lower expression levels. This is likely due to the
HIF-1-mediated up-regulation of PHD2, which retains enough activity to hydroxylate HIF-1α, resulting
in its renewed degradation [29]. Cycling hypoxia results in an enhanced activity and stabilization of
HIF-1α, which is at a much greater level than that in chronic hypoxia [30]. This damaging phenotype,
where HIF-1α is accumulated, is also associated with an increased resistance to radiotherapy and
chemotherapy as well as increased metastatic potential [12].
During hypoxia, HIFs support and even enhance the metabolic reprogramming of glycolysis
through the up-regulation of almost all glycolytic genes, like hexokinase 1 and 3, aldolase A and
C and glyceraldehyde 3-phosphate dehydrogenase-6, and the monocarboxylate transporters that
export lactate.
HIFs also regulate a set of genes involved in extracellular matrix remodeling, migration and
digestion of the basement membrane. This group includes vimentine, fibronectine, keratins, matrix
metalloproteinase 2, and cathepsin D that is associated with a concomitant loss of E-cadherin, a crucial
feature of epithelium-mesenchyme transition [31]. The principal HIF-1α regulated genes are reported
in Figure 3.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 6 of 21 
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dehydrogenase A; LEP, leptin; LRP1, Low density lipoprotein receptor-related protein 1; LDL-receptor-
related protein 1; MDR1, multidrug resistance 1; MMP2, matrix metalloproteinase 2; NOS2, nitric oxide 
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phosphofructo-2-kinase/fructose-2,6-biphosphatase-3; PFKL, phosphofructokinase L; PGK 1, 
phosphoglycerate kinase 1; PKM, pyruvate kinase M; TGF-α, transforming growth factor-α; TGF-β3, 
transforming growth factor-β3; TPI, triosephosphate isomerase; VEGFA, vascular endothelial growth 
factor A; UPAR, urokinase plasminogen activator receptor; VEGFR2, VEGF receptor-2; VIM, vimentin. 
2.3. ROS Production in Tumor Microenvironment 
ROS are a broad class of oxygen radical species that are produced in cells as normal by-products 
of metabolic processes. They are characterized by heterogeneous properties and have a plethora of 
downstream effects, depending on their concentrations. Under physiological conditions the 
continuous production and detoxification of cellular ROS lead to a tightly controlled and well-
balanced redox status. On the other hand, an imbalance between ROS production and removal results 
in the accumulation of ROS in the cells and leads to oxidative stress. In order to maintain the redox 
balance, cells activate some ROS scavenging systems, mainly composed of antioxidant enzymes and 
non-enzymatic ROS scavengers. Common enzymes that are involved in the detoxification process of 
ROS are superoxide dismutase, catalase, peroxiredoxins, and glutathione peroxidases. For their 
reducing power, glutathione and NAD(P)H are the most well-known electron donors [32]. 
ROS and associated oxidative stress have been historically considered harmful to the cell as they 
can damage cellular DNA, oxidize fatty acids and aminoacids. The effects of this oxidation lead to 
tissue destruction associated with various diseases. 
TME is characterized by elevated ROS levels that trigger oxidative stress, deeply affecting tumor 
progression and metastasis. This condition results from increased basal metabolic activity, 
mitochondrial dysfunction, peroxisome activity, uncontrolled growth factors and cytokines 
signalling, and oncogene expression [30]. On the other hand, some ROS source enzymes, as NADPH 
oxidase (NOXs), cyclooxygenases (COXs), or lipoxygenases (LOXs)s, present higher enzymatic 
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ALDA, aldolase A; AK3, adenylate kinase 3; ALDC, aldolase C; AMF, autocrine motility factor; CA
9, carbonic anhydrase 9; CATHD, cathepsin D; ENG, endoglin; ET1, endothelin-1; ENO1, enolase 1;
EPO, erythropoietin; FN1, fibronectin 1; GLUT1, glucose transporter 1; GLUT3, glucose transporter 3;
GAPDH, glyceraldehyde-3-P-dehydrogenase; HK1, hexokinase 1; HK2, hexokinase 2; IGF2, insulin-like
growth-factor 2; IGF-BP1, IGF-factor-binding-protein 1; IGF-BP2, IGF-factor-binding-protein 2; IGF-BP3,
IGF-factor-binding-protein 3; KRT14, keratin 14; KRT18, keratin 18; KRT19, keratin 19; LDHA,
lactate dehydrogenase A; LEP, leptin; LRP1, Low density lipoprotein receptor-related protein 1;
LDL-receptor-related protein 1; MDR1, multidrug resistance 1; MMP2, matrix metalloproteinase 2;
NOS2, nitric oxide synthase 2; OH-1, heme oxygenase 1; PAI1, plasminogen-activator inhibitor 1;
PFKBF3, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-3; PFKL, phosphofructokinase L; PGK 1,
phosphoglycerate kinase 1; PKM, pyruvate kinase M; TGF-α, transforming growth factor-α; TGF-β3,
transforming growth factor-β3; TPI, triosephosphate isomerase; VEGFA, vascular endothelial growth
factor A; UPAR, urokinase plasminogen activator receptor; VEGFR2, VEGF receptor-2; VIM, vimentin.
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2.3. ROS Production in Tumor Microenvironment
ROS are a broad class of oxygen radical species that are produced in cells as normal by-products
of metabolic processes. They are characterized by heterogeneous properties and have a plethora of
downstream effects, depending on their concentrations. Under physiological conditions the continuous
production and detoxification of cellular ROS lead to a tightly controlled and well-balanced redox status.
On the other hand, an imbalance between ROS production and removal results in the accumulation of
ROS in the cells and leads to oxidative stress. In order to maintain the redox balance, cells activate
some ROS scavenging systems, mainly composed of antioxidant enzymes and non-enzymatic ROS
scavengers. Common enzymes that are involved in the detoxification process of ROS are superoxide
dismutase, catalase, peroxiredoxins, and glutathione peroxidases. For their reducing power, glutathione
and NAD(P)H are the most well-known electron donors [32].
ROS and associated oxidative stress have been historically considered harmful to the cell as they
can damage cellular DNA, oxidize fatty acids and aminoacids. The effects of this oxidation lead to
tissue destruction associated with various diseases.
TME is characterized by elevated ROS levels that trigger oxidative stress, deeply affecting
tumor progression and metastasis. This condition results from increased basal metabolic activity,
mitochondrial dysfunction, peroxisome activity, uncontrolled growth factors and cytokines signalling,
and oncogene expression [30]. On the other hand, some ROS source enzymes, as NADPH oxidase
(NOXs), cyclooxygenases (COXs), or lipoxygenases (LOXs)s, present higher enzymatic activity
in TME [33,34]. Thus, the adaptations to oxidative stress, together with the intrinsic metabolic
reprogramming of cancer cells lead to profoundly altered ROS production and sustained oxidative
stress in tumor tissue [35,36]. It is important to underline that cells respond to ROS burst activating the
detoxification systems with an increase of glutathione and NAD(P)H synthesis that result in a more
reducing environment. As a consequence, oxidant-sensitive transcription factors like HIF-1, NF-κB or
STAT3 become active and play a mandatory role in eliciting a pro-migratory and pro-inflammatory
response in cancer cells [37–40].
These signaling pathways in TME contribute to render cancer cells even more resistant to
a variety of stresses including anticancer drug exposure or mechanical forces when entering the
bloodstream [16,41].
3. Tumor Dormancy and the Interplay with the Tumor Microenvironment
Metastatic disease rather than primary tumor is one of the major causes of death among cancer
patients. In some instances, this occurs shortly after primary tumor detection and treatment because
tumor cells are already expanding at the moment of the diagnosis. However, in many types of tumors,
metastatic diseases occur years or decades after tumor resection. The appearance of tumor relapse
after a prolonged time is explained by the survival of disseminated tumor cells (DTCs) in a dormant
state. These cells survive in a quiescent state and remain undetected for long periods, explaining the
prolonged asymptomatic residual disease and treatment resistance.
The period between primary tumor detection and metastatic relapse is often defined as tumor
dormancy, a poorly understood stage in cancer progression in which cells are characterized by mitotic
cycle arrest in G0/G1 phase and low metabolism [42]. This state is reversible, and the dormant cells can
re-enter in the cell cycle to proliferate again under certain conditions, such as induction by growth
factors, cytokines, nutrients, or chemical agents.
Dormant cells present different genes expression profiles respect to parental cells. As described
by Kim et al., the up- and down-regulation of some genes is an important event in the mechanisms
of dormancy onset and maintenance of dormancy [43]. The manipulation of the expression of
dormancy-associate genes has been proposed as new therapeutic approach. Recently, Tiram et al.
validated the role of two genes from signature, thrombospondin-1 (TSP-1) and epidermal growth factor
receptor (EGFR), as regulators of glioblastoma dormancy and explored their therapeutic potential in
glioblastoma treatment [44].
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Tumor dormancy results from tumor cell growth arrest (cellular dormancy) and from mechanisms
that antagonize the expansion of a dividing tumor cell population (tumor mass dormancy). The first
one can occur when tumor cells enter a state of quiescence. In this regard, the absence of proliferation
in dormant cells has been attributed to the up-regulation of cell cycle inhibitors such as p21 and p27.
Conversely to single cell dormancy, tumor mass dormancy is characterized by proliferating cells
able to form micrometastatic lesion that does not expand beyond a certain size. It seems to be caused
by a balance of cells proliferation and apoptosis, regulated by pro-angiogenic proteins and angiogenic
inhibitors produced by tumor and stromal cells, as well as immunological switches. This phenomenon
is also termed angiogenic dormancy [45]. According to this definition, Naumov et al. sustain that a
failure to activate the angiogenic switch contributes to maintain a group of cells in a dormant state [46].
Indraccolo et al. reported that a short-term perturbation in a transient angiogenic burst could be
sufficed to interrupt tumor dormancy [47]. In this regard, therapeutic strategies to target tumor
vasculature, such as anti-VEGF drugs, are the current approaches to oppose dormant cells.
Tumor mass dormancy can be also maintained by the immune system that controls and does
not completely eliminate malignant tumor growth. This process is termed immunologic dormancy,
and given that tumor cells are inherently genetically unstable, the strong immune pressure placed on
tumor cells in equilibrium makes them susceptible to acquire mutations that may allow for immune
evasion. These adapted tumors frequently defect in antigen presentation, processing, or both, through
the loss of major histocompatibility complex (MHC) class I or latent membrane protein (LMP)-family
molecules, rendering them undetectable by the adaptive immune system. They are also capable
of establishing a global immunosuppressive state in the TME by secreting some cytokines, such as
TGF-β and VEGF, or by recruiting immunosuppressive cell type, including T regulatory cells and
myeloid-derived suppressor cells (MDSCs). These recruited cells contribute to the anti-inflammatory
cytokine production and suppress the anti-tumorigenic capacities of the other immune cell types.
Once micrometastases overcome dormancy, they become receptive to signals and cell types within the
TME to support their expansion. Thus, controlled immune activation, marked by an induction of T
cells, is a promising avenue to force tumor dormancy [45].
To date, little is known regarding tumor dormancy and the biology of dormant cells. Nevertheless,
it is clear that one major driving force for tumor dormancy is cellular environment, which poses a
challenge to the cells regarding survival and proliferation. Indeed, cells enter or escape dormancy
according to restrictive or permissive microenvironment, adapting themselves to better serve its needs.
In the restrictive TME, one of the early responses of tumor cells is to reduce growth and the rate of
oxygen consumption. Using immunocytochemical techniques, some researchers have demonstrated
that hypoxic tumor cells are in a non- or slow-proliferating state and a majority of these cells are negative
for proliferation markers, such as Proliferating Cell Nuclear Antigen (PCNA) or Bromodeoxyuridine
(BrdU). According to these evidences, the link between cellular dormancy and TME is highlighted by
the fact that if the dormant DTCs are originated from the hypoxic niche of the primary tumor, they may
be already pre-programmed to be growth-arrested and enter a dormant state before to reach other
sites. On the other hand, the inductor of dormancy can be the restrictive microenvironment of the
target organs where the DTCs arrive.
However, whether hypoxia signaling prepares a “metastatic soil” in distant organs to remain in
a prolonged state of dormancy is not well clarified. However, in several different types of cancers,
the bone marrow is a common homing organ for DTCs. In most studies, DTCs are detected in the
hypoxic regions of bone marrow and persist there over many years with the potential to recirculate to
other organs.
A recent study demonstrated that hypoxic microenvironments in the primary tumor give rise to
a subpopulation of DTCs programmed to become dormant [48]. In addition, hypoxia is considered
to be a major feature of the TME and is a potential contributor to the CSC phenotype and its
enhanced tumorigenicity. This means that hypoxia may contribute to cancer dormancy through
different pathways that may be interconnected [49,50]. Moreover, tumor cells adaptation to hypoxic
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TME is regulated by the expression of more than a hundred genes involved in various biological
processes [51–55]. One of them is the epithelial-mesenchymal transition (EMT) where the cancer cells
lose the epithelial phenotype and acquire mesenchymal features [56–58].
Hypoxia induces EMT by up-regulation or repression of EMT-associated transcription factors such
as HIF1-α, NF-Kβ and Notch [59,60]. In particular, the best characterized of them, HIF-1α, induces
EMT through the induction of transcription of SNAIL, ZEB1, TWIST and TCF3 [61,62].
EMT induced by hypoxia is a key factor in cancer resistance to apoptosis, to chemotherapy and
to the immune response. EMT is one of the initiating events required for the migration into blood
vessels of DTCs. Indeed, many studies have demonstrated the hyperexpression of EMT markers in
DTCs [63,64].
Hypoxia and HIFs are known to have a role in promoting tumor cell dedifferentiation toward a
stem-like phenotype. In order to maintain the self-renewal propriety, hypoxia and HIFs induce the
expression of OCT4, SOX2 and NANOG genes [65–67].
Signaling Mechanisms in Tumor Dormancy
To date, several cancer cell-intrinsic pathways that lead to cellular dormancy have been described.
The first signaling mechanism that has been connected with cell proliferation and DTC dormancy
was the balance between the activities of the mitogen-activated protein kinases (MAPKs) ERK1/2
and p38 [68]. In particular, the switch toward phosphorylation of ERK1/2 favors proliferation,
while predominant phosphorylation of p38 lead to quiescence. It is now well accepted that in
a permissive microenvironment, the interaction between DTCs and extracellular matrix as well
as stromal cells results in the activation of mitogenic signaling (high p-ERK/p-p38) that promote
cell growth. Conversely, in restrictive microenvironment, where the activation of stress signaling
occurs, low p-ERK/p-p38 ratio represents the molecular switch for induction of a prolonged phase
of dormancy [69]. The activities of these kinases were found to be driven by the interaction of
urokinase-type plasminogen activator receptor (uPAR), α5β1 integrin, fibronectin focal adhesion
kinase (FAK) and Src-kinases. It has been demonstrated that proliferating cells are characterized by
high expression of uPAR that lead to activation of Src-kinase resulting in the ERK1/2 phosphorylation.
Increased level of fibronectine also results in ERK1/2 phosphorylation. Conversely, p38 phosphorylation
is favored when uPAR expression is lost and fibronectin is absent [70–72].
Recently, it has been shown that transforming growth factor β2 (TGFβ2) activates p38 in
cancer cells disseminated to bone inducing dormancy. This correlates with up-regulation of the
proliferation inhibitor p27 and down-regulation of cycling-dependent kinase 4 (CDK4). In this regard,
an up-regulation of TGFβ2 and p27 expression induced by hypoxia has been shown in dormant cancer
cells, confirming a key role of hypoxia on dormancy [73].
Moreover, phosphorylation of p38 leads to the activation of the unfolded protein response (UPR)
pathway, which promotes cells survival and dormancy. Some studies from Aguirre-Ghiso laboratory
highlight that, although all the three sensors of UPR, PERK, ATF6, IRE1 are activated in dormant
human epidermoid carcinoma HEp3 cell, only PERK activation contributes towards the growth arrest
of cells [70,74–76]. This occurs by attenuating translation of G1-S transition regulators such as cyclin
D1, D3 and CDK4. On the other hand, the activation of both ATF6 and IRE1 are required for the
basal adaptation and cell survival in restrictive microenvironment. This occurs in part via the ATF6
mediated Rheb induction and a strong inhibition of mTOR signaling (Figure 4) [77].
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Figure 4. Signaling pathways involved in the switch between proliferation and dormancy. Proliferation
to dormancy switch seems to be mediated by interactions between surface receptors such as UPR
and integrins, mitogenic signaling from the Ras-extracellular signal-regulated kinase (ERK) pathway,
and stress induced signaling from the p38 pathway. In particular, the switch toward phosphorylation
of ERK1/2 favors proliferation, while predominant phosphorylation of p38 leads to a G0/G1 arrest,
growth arrest and survival that result in dormancy.
Recently, it has been demonstrated the key role of the suppression of PI3K/AKT pathway in the
induction of tumor dormancy as well as in the survival disseminated tumor cells [69]. PI3K/AKT
signaling regulates cell proliferation, survival and metabolism in cancer cells and it is frequently
constitutively activated in multiple human cancers [78]. Under a prolonged lack of nutrients,
the suppression of AKT ctivity is necessary for prese vi g the energy sourc , d reasing energy demand
and act vating a strategy of cancer cel s to su vive in a chro ically deteriora d microenvironment [79].
The mechani m by which AKT activity is supp essed is not completely understo d. It may involve
different steps in the PI3K/AKT signaling such s inappropriate activation of rec ptor tyrosine kinase
(RTK), inactivation of upstream kinases, i.e., PI3K, activation of phosphates PTEN or/and inactivation of
mTORC1 (Figure 5). PI3K/AKT axis directly inhibits glycogen synthase kinase 3-beta, which normally
suppresses proliferation, and activates the canonical cell cycle pathway. Conversely, the suppression of
AKT that occurs in dormant state, allows to activate both CDKs inhibitors p21 and p27 that arrest cell
cycle, and the autophagic machinery that protects cells during starvation or stress condition [80].
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4. Cancer Stem Cells in Tumor Microenvironment
Recent studies indicate the presence of a s all, intra-tu oral subpopulation of tumor-initiating
cancer cells with der gulated stem-cell-like properties t t l t e to be resistant to conventional
therapies. Thes tumorigenic cancer cel s, c r te ce ls (CSCs), may be the linchpins of
disease r currence and may significantly contribute to et
Specifically, CS s exhib t a functional stemness si rising self-renewal and ability to
differentiate into multiple can er lls [81]. Self-renewal is a ch racteriz d mitotic cell division in which
a stem cell originates one or two undifferentiated cells perpetuating the stem cell pool. On the other
hand, the stem cells differentiate into more specialized cell types generating all the diverse cellular
phenotypes of the primary lesion [2]. Evidence supports the vital role of this subset of cells in the
initiation and maintenance of a tumor in addition to their capability to dictate invasion, metastasis,
heterogeneity, and therapeutic resistance.
4.1. Cancer Stem Cells Markers
Since CSCs are endowed with enhanced tumorigenic potential and multidrug resistance,
their specific elimination may represent one of the most important challenges of current cancer
research. To achieve better understanding and treatment of CSCs, we must identify better the markers
of stemness in order to isolate CSCs and analyze their biological characteristics to target them efficiently
for therapeutic purposes. Therefore, the identification and isolation of these CSCs using putative
surface markers have been a priority of research in cancer. However, the definition of specific CSCs
surface markers in all cancer types requires further investigation and effort because the heterogeneity
among tumors makes it difficult.
CSC markers must be clearly defined for each tissue, and investigation is needed to determine
combinations of target antigens that show high co-expression of surface markers. Some molecules
(such as CD133, CD44, ABCG2, ALDH) are already used as biomarkers of some kind of cancer stem cells,
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but many other cell surface proteins have been identified as the marker of many tumors in the recent
years. Identification and checking of the expression of new CSC markers could amplify combinatorial
targeting strategies with well-matched target antigens enhancing the therapeutic efficacy. Haubner et
al. indicate that combinatorial targeting of CD33/TIM3 or CLL1/TIM3 may enhance therapeutic efficacy
without aggravating toxicity in immunotherapy of AML Leukemia [82]. Skoda et al. emphasize the
need for further studies that would investigate whether CD24+/CD44+/EpCAM+/CD133+ phenotype
specifically identifies pancreatic CSCs [83].
CSCs selection and evolution are influenced by TME that provides a breeding ground to maintain
a more stem-like and undifferentiated phenotype. For instance, hypoxia exerts a selective pressure on
the CSCs population contributing directly to the development of more aggressive cancer cells and
resistance to therapies [84,85]. Recently, it has been demonstrated that prolonged hypoxia exposure
results in the induction of genes essential for stem cell function such as Oct4, Nanog and c-Myc.
These genes are regulated by HIFs, in particular the isoform HIF-2α, which is specifically involved
in the self-renewal and multipotency of CSCs. Molecular database analyses revealed that HIF-2α
expression correlates with poor outcome of patients with metastasis and represent a promising target
for the eradication of CSCs in cancer therapy [86].
4.2. Tumor Dormancy and Cancer Stem Cells
There is a tight and complex relationship between stemness and dormancy even if the ability of
CSCs to proliferate and initiate robust tumor outgrowth seems to be incompatible with a cancer dormant
state. Elegant studies provide strong evidence for the existence of dormant cells as a subpopulation of
CSCs in different tumors such as breast, colon, pancreas and ovary [87–91]. Nevertheless, it is important
to note that not all dormant cells have the stem like properties of self-renewal and differentiation [92].
Unlike dormant tumor cells that can remain quiescent for several years, it is not clear if CSCs
undergo so long phase of quiescence. However, it is well described that these dormant CSCs exploit
phases of cellular dormancy to ensure tumor maintenance and survival in harmful TME, including
growth-inhibitory niches and cytotoxic milieus.
It is clear from the previous discussion that hypoxic TME maintains an undifferentiated and
quiescent state of CSCs and, since hypoxia promotes tumor dormancy, it could be one of the key
links between the dormancy and the stemness. How the hypoxia triggers CSCs populations towards
quiescence is still unclear even if some improvements are carried out. It has been demonstrated that
slow-cycling CSCs are more likely localized in the low oxygen area of the tumor, away from the blood
vessels whereas the fast-cycling cells with limited self-renewal capacities, reside in areas much closer
to the vasculature [93].
Moreover, several studies have unraveled intriguing parallels between the mechanisms regulating
CSCs behavior and angiogenic control of tumor dormancy. While CSCs might survive in the angiostatic
environments associated with dormancy, they also promote cancer vascularization in settings of tumor
outgrowth [94,95]. Since CSCs own the ability to promote tumor progression by triggering angiogenic
responses, they are likely to represent the dormant tumor populations ultimately responsible for
delayed cancer recurrences [93].
Another direct link between CSCs and dormant tumor populations is their converging to survive
cancer therapy. Indeed, dormant cells are often spared by current treatment modalities, as determined
in both animal models and clinical disease [96,97]. Similarly, CSC frequencies are enhanced in metastatic
tumor recurrences post-therapy compared to those in pre-therapy samples. Importantly, therapeutic
refractoriness of tumor dormant cells is attributable to several resistance mechanisms also intrinsic to
the CSCs compartment, including impairment of cancer apoptotic pathways, alterations of cell cycle
checkpoints, and reduced drug accumulation [98].
Taken together these findings highlight the critical importance of TME in the biology of CSCs that
creates a strong relationship with tumor dormancy.
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However, in light of the intriguing discussion between CSCs biology and the mechanisms
controlling tumor dormancy, insights from CSCs biology could help the future research on
tumor dormancy.
5. Autophagy in Tumor Microenvironment
Autophagy, or type II programmed cell death, is a catabolic process, evolutionarily conserved
and genetically controlled, whereby cells self-digest intracellular organelles to remove those with
compromised function and to maintain cell homeostasis. However, autophagy can also be considered a
temporary survival mechanism during periods of starvation where self-digestion offers an alternative
energy source and may facilitate the disposal of unfolded proteins under stress conditions. The catabolic
function provided by autophagy is thereby suppressed once the external nutrient supply is adequate to
support cellular metabolism. Besides starvation, autophagy can be also activated by other physiological
stress stimuli, such as hypoxia, endoplasmatic reticulum stress, high temperature, hormonal stimulation
or pharmacological agents [99].
Depending on the mode of cargo delivery to the lysosome, autophagy can be subdivided
into three subtypes: chaperon-mediated autophagy, microautophagy and the most studied process
named macroautophagy [100]. Chaperone-mediated autophagy involves the direct translocation
of cytosolic proteins across the lysosomal membrane, by molecular chaperones (e.g., the 70 kDa
heat shock cognate protein, Hsp70). Microautophagy involves inward invagination of lysosomal
membrane, which delivers a small portion of cytoplasm into the lysosomal lumen. Macroautophagy
is the most efficient autophagic clearance mechanism and the most common type of autophagy,
therefore, hereafter macroautophagy will be referred to as autophagy. Macroautophagy is a process
conserved by yeast to mammals and is mediated by a double-membrane special organelle termed
autophagosome. Upon induction, a small vesicle (phagophore) elongates and encloses a portion
of cytoplasm, which results in the formation of the autophagosome. Then, the outer membrane of
the autophagosome fuses with a lysosome to form an autolysosome, leading to the degradation of
the enclosed materials together with the inner autophagosomal membrane. Aminoacids and other
small molecules that are generated by autophagic degradation are delivered back to the cytoplasm for
recycling or energy production [101]. Specifically, the process of autophagosome formation involves
two major steps, nucleation and elongation of the isolation membrane, in which different proteins,
such as the products of AuTophaGy-related (Atg) genes and microtubule-associated protein light
chain 3 (LC3) are involved [102]. LC3 is one of the best characterized protein on autophagosome, and
therefore, it serves as widely used marker of autophagy [103]. It is expressed in cells as a full-length
cytosolic protein that, upon autophagy induction is proteolytically cleaved, to generate LC3-I that is
conjugated with phosphatidylethanolamine and forms LC3-II (Figure 5) [104–106].
Among the numerous components involved in the regulation of autophagy, the mammalian
target of rapamycin (mTOR) is now recognized as sensor that co-ordinately regulates the balance
between growth and autophagy in response to cellular physiological conditions and environmental
stress [107]. mTOR is a serine/threonine protein kinase that belongs to the phosphatidylinositol
kinase-related kinase (PIKK) family. The inhibition of mTOR activity through Akt and MAPK signaling,
under nutrient starvation, induces autophagy as well as negative regulation of mTOR, through AMPK
and p53 signaling, promotes it (Figure 6) [108].
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Autophagy Sustains Survival of Dormant Cancer Cells
A potential role of autophagy in dormancy was originally evidenced in C. elegans during a
dormancy-like state, where larvae are exposed to hostile microenvironment. In this model, C. elegans
activated autophagy that could promote survival during quiescent states [114].
Since autophagy is activated in response to changes of the microenvironment, it could be interesting
to investigate the mechanisms that induce autophagy and allow to the survival and the maintenance
of the dormant state in tumor cells. Although the efforts to show through in vitro or in vivo models,
the role of autophagy in dormancy and the mechanisms that are activated during this state remain
largely discussed. However, studies in models of breast cancer cells suggest that the decreased
mitogenic signaling of β1-integrin in dormancy may stimulate autophagy [115]. Moreover, it has been
shown that d rmant cancer cells activate p27 that is involved in cell cycle arrest and directly induces
autophagy to facilita e cells survival in response growth factor withdrawal [116,117].
It would be criti al to determine whet er autophagy lays a dormant or survival-inducing role,
or both, in quiescence tumor ce ls. If utophagy i duces a pro-survival stat , then strategies to bl ck it
could eradicate dormant cells. In case that it contributes to both quiescence and survival, then more
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detailed analysis of these pathways would be required to reveal ways to inhibit only the survival
signals without interrupting quiescence [118].
6. Models for the Study of Dormancy
FDA approved cancer drugs are usually optimized to be highly effective in vitro using cancer
cells monolayers and in vivo using mouse xenograft cancer models [119–121]. However, considering
the complexity of tumors, there is a gap between these two models. In fact, the design of innovative
therapies for effective cancer therapy require adequate preclinical models that mimic TME. With that
purpose, cell and tissue engineered tumor models have been gaining attention since they can recapitulate
more closely the TME to which the cells within the tumor are exposed (e.g., survival, proliferation,
gene expression heterogeneity and multidrug resistance), also enabling the control of environmental
factors and measurement of cell responses [122,123]. Experiments conventionally start on 2D models,
providing initial improvements using monocultures of commercial/immortalized cell lines, in a simple,
convenient and relatively reproducible way. These 2D cultures can be improved by using co-cultures of
different cell types to better resemble human tissues cell-to-cell communications [124,125]. To improve
even more tissue complexity (mechanical and biochemical signals), mimicking the tumor architecture,
3D (co-)culture systems have been employed [119,126]. The development of more biologically relevant
in vitro tumor models using 3D approaches not only results in improved translation but also contributes
to reducing animal testing (three Rs politics) required by the pharmaceutical industry and governmental
institutions [126,127].
However, in vitro models to induce dormancy in tumor cells are still few. Those models have been
classified according to the dormancy-inducing sources that are used [128]. Herein, we will focus on the
in vitro dormancy models that use hypoxia to mimic the stressful TME. The simplest model to achieve
hypoxic 2D cultures is to incubate cells in a hypoxic chamber. Louie et al. have shown that, exposing the
metastatic human breast cancer cell lines MDA-MD231 and BCM2 to hypoxia (1% O2)/reoxygenation
cycles, a unique sub-population can be selected. This population is able to quickly form colonies
and present both stem-like and EMT (epithelial mesenchymal transition) phenotypes. Moreover,
CSCs are highly tumorigenic when injected into immune-deficient mice [129]. Recently, we have
obtained and characterize the chronic hypoxia resistant MDA-MB-231 (chMDA-MB-231) cell line.
ChMDA-MB-231 cells are the sub-population selected from MDA-MB-231 exposed to at least three
hypoxia/reoxygenation cycles that present stem-like phenotype and spheroid forming ability. We have
shown how this hypoxia-resistant breast cancer cell line manage to survive to hypoxic/reoxygenation
stress by entering into a reversible dormant state defined by low metabolism, arrest in G0/G1 phase
and decreased proliferation rate. Furthermore, we proposed a survival mechanism founding that in
chMDA-MB-231 cells autophagy is strongly induced [84]. It has been shown that also a pancreatic cell
line, AsPC-1, is uncommonly able to survive under chronic hypoxia (1% O2) for weeks entering in a state
of dormancy. It has been shown that the induction of dormancy using hypoxia can be observed also
in primary cultured cells derived from lung, colorectal and urothelial cancer, but this model requires
both chronic hypoxia and growth factor deprived conditions [79]. Besides using the hypoxic chamber,
it is possible to obtain a hypoxia-mimicking microenvironment adding iron-binding/substitute agents,
such as di cobalt chloride (CoCl2), in cell culture medium. This hypoxia-mimetic agent is able to
stabilize cytosolic expression of HIF1α, one of the major regulators of hypoxia signaling, inhibiting
its degradation. In vitro cancer cells dormancy hypoxia-regulated can be induced and maintained by
addition of CoCl2 in cultures of breast cancer MCF-7, MDA-MB-231 and ovarian cancer OVCAR-3
cell lines. The dormancy responses obtained in this model is comparable to cells maintained in 0.1%
O2 conditions [130]. Finally, a different in vitro model of hypoxia-induced tumor dormancy can be
achieved also imposing a diffusion-limited hypoxia culturing cells in 3D hydrogel systems that, limiting
the access of oxygen and nutrients, led to reduced cells proliferation and cellular quiescence. Prostate
cancer cells C4-2B, colon cancer cells HCT116, and breast cancer cells MDA-MB-231 have been cultured
in a transglutaminase-crosslinked gelatin gel, called Col-gel, for a few days. Increasing culture time,
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up to nine days, it has been observed a gradual lowering of nutrient diffusion and of oxygen levels
at the center of the Col-gel culture causing a higher proliferation of the peripheral cells, that forms
spheroids and clusters, and inducing quiescence or necrosis of the inner ones. This system has been
also used to mimic the tumor niche in a co-culture model of human squamous carcinoma cells (SCC-71)
and bone marrow derived mesenchymal stem cells [131]. As evidenced by these newly established
in vitro models, the development of systems to mimic hypoxia-induced tumor dormancy is a functional
approach to study the mechanism that regulate both primary and disseminated tumor development.
7. Prospective
The hypoxic tumor microenvironment has been recognized as a cause of malignancy or resistance
to various cancer therapies. However, the effect of a chronic exposure of the cells to hypoxia and
the following reoxygenation cycles remain elusive. Although most of the tumor cells die in chronic
hypoxia, some of them can survive for more than several days in a quiescent state. This dormant state
is reversible, with tumor cells recovering the ability to self-renew once closed vessels reopen or new
vasculatures reach the hypoxic area. Because dormant tumor cells may be the founders of metastasis,
one hypothesis is that these cells share stem cell-like characteristics that may be responsible for their
long life.
An understanding of the regulatory machinery of tumor dormancy is essential for identifying
early cancer biomarkers and could provide a rationale for the development of novel agents to target
dormant tumor cells population. The lack of established in vitro models of tumor dormancy represents
the main factor that hampers the understanding of dormant cell responses. Indeed, the majority of
in vitro hypoxia studies have been carried out exposing cell lines to acute hypoxia (3–24 h), whereas
only few reports of chronic hypoxia have been published.
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